UK approval for Daiichi Sankyo’s cholesterol-lowering treatments
In the UK, over seven million people are affected by cardiovascular disease
Read More
Tag: cholesterol
NHS to review making statins available for pharmacists
If only 45% of people with a high risk of cardiovascular disease were identified and treated, 6,000 strokes and heart attacks could be avoided over the next ten years.
Read More
Evinacumab hits targets in late-stage cholesterol trial
On average patients entered the trial with LDL cholesterol levels of 255 mg/dL, despite treatment with other lipid-lowering therapies.
Read More
Statins may help treat serious mental illness
Statins could bring significant benefits to people with serious mental illnesses such as schizophrenia, bipolar disorder or non-affective psychoses, indicate new findings from UCL-led research.
Read More
Daiichi & Esperion agreement for Bempedoic Acid
Daiichi Sankyo Europe has entered into a European licensing agreement with Esperion for bempedoic acid, and the bempedoic acid/ezetimibe combination tablet.
Read More
Sanofi, Regeneron to cut price of Praluent
Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
Read More
FDA approves heart protection label change for Repatha
US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease.
Read More
MSD pulls plug on cholesterol drug anacetrapib
MSD has decided to pull the plug on its late-stage cholesterol drug anacetrapib after a review of clinical data.
Read More
Pfizer pulls plug on PCSK9 inhibitor bococizumab
Pfizer is terminating its clinical development programme for investigational PCSK9 inhibitor bococizumab, which was being assessed by the firm for reducing cholesterol.
Read More
Praluent slashes need for apheresis treatment
Sanofi/Regeneron’s cholesterol buster Praluent reduced the need for apheresis treatment in patients with very high cholesterol by 75 percent versus a placebo, show findings from the Phase III ODYSSEY ESCAPE trial.
Read More
AZ files suit against FDA to prevent Crestor generics
AstraZeneca has filed a lawsuit to prevent the US Food and Drug Administration from approving the sale of generic versions of its multi-billion-dollar cholesterol drug Crestor.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
